Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Harmony Biosciences Holdings, Inc.

HRMY ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$41.54

▲ +0.05%

Market Cap $2.42B · Vol 253.01K

Key Metrics

P/E Ratio

13.44

FWD: 9.69

Market Cap

$2.42B

Mid Cap

Div Yield

N/A

EPS Growth

+50.80%

YoY

RSI (14)

67.55

Momentum

Beta

1.00

vs Market

52W High

$43.49

4.48% below

52W Low

$25.52

62.77% above

Volume

253.01K

Avg 274.06K

P/B

2.48

Price-to-book

ROE

20.75%

Return on equity

Free Float

87.26%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Harmony Biosciences Holdings, Inc. (HRMY) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HRMY pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.68%

+8.97%

+20.55%

+50.45%

YTD

+11.01%

+28.25%

+10.71%

+16.65%

Financials & Valuation

TTM · Annual

Total Revenue	$868.45M
Net Income	$158.69M
Revenue Growth (YoY)	+30.32%
Gross Margin	77.16%
Operating Margin	24.00%
Net Profit Margin	18.27%
ROE	20.75%
ROA · ROIC	18.94% · 18.05%

P/E Ratio	13.44
Forward P/E (FY1)	9.69
PEG Ratio	1.77
P/S	2.52
P/B	2.48
P/FCF	6.67
EPS Growth	+50.80%
Outstanding Shares	58.24M

Technical Indicators

50-Day SMA	$38.11
200-Day SMA	$34.42
RSI (14)	67.55
Beta	1.00
52-Week High	$43.49
52-Week Low	$25.52

Volume Today	253.01K
Avg Daily Volume (30D)	274.06K
Relative Volume	0.92x
Volatility (10D)	32.95
Volatility (30D)	38.17
Free Float	87.26%

Analyst Consensus

BUY

Current Price $41.54

Mean Target $47.36

52W Low$25.52 52W High$43.49

Current

Target

$25.52 $43.49

Current Analyst target

+14.02% upside potential · 11 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00WBPG548

ISINUS4131971040

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Company +2.02% JNJ Johnson & Johnson +0.28% ABBV AbbVie Inc. +1.81% NVS Novartis AG +1.33% NOVN.S Novartis AG +1.68%

Company Profile

Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.